Conceptual visualization of an AI virtual cell

AI VIRTUAL CELL PLATFORM

Model the cell.
Move discovery
forward.

From real biological data to disease dynamics, virtual perturbations and experimental validation. Clearer evidence for every research decision.

BIOLOGICAL DATA · COMPUTATIONAL MODELS · VALIDATION
10+Core models & algorithms
4Applications, one platform
PCLSHuman lung tissue validation
AgentFrom research requests to reports

01 / THE PLATFORM

From cellular signals
to testable decisions.

A continuous research workflow connects data, models, candidates and validation results. Each project contributes reusable knowledge and model assets.

MIMESIS / VIRTUAL CELL

Turn biological complexity
into research priorities.

High-resolution representations × disease dynamics × mechanisms

  1. 01

    Real-world data

    Single-cell, multi-omics, spatial transcriptomics, pathology images and clinical outcomes.

    scRNA / scATAC / Spatial / Clinical
  2. 02

    Cell & disease models

    High-resolution cell representations, cross-modal alignment, cohort expansion and disease trajectories.

    DOLPHIN / MATES / scCross / scGALA / scSemiProfiler
  3. 03

    Virtual interventions

    Simulate drug and gene interventions to rank candidates, identify responsive cell types and explain key mechanisms.

    UNAGI / CellAgentChat / DENetwork / SIDISH / veloAgent
  4. 04

    Validation & delivery

    Connect with cell, organoid, organ-on-chip and human tissue studies to deliver reports and candidate packages.

    Top List / Candidate Package / SaaS / API

02 / FOUR APPLICATIONS

One scientific foundation.
Four paths to impact.

The disease, cohort or efficacy question determines the models, deliverables and validation approach.

01

Drug discovery

Pharma · Biotech · CROs

Find intervention opportunities in disease trajectories. Prioritize targets, drugs and combinations, then connect candidates with experimental validation.

Disease models / Top lists / Candidate packages
02

Precision medicine

Hospitals · Clinical research teams

Bring together single-cell data, multiple modalities and clinical outcomes for patient stratification, high-risk cell analysis and reviewable agent-generated research reports.

Cohort analysis / SIDISH Agent / On-premises deployment
03

Healthy aging

Health management · Aging research

Build individual and population cell-state models, prioritize intervention ingredients and refine assessments through longitudinal profiling and follow-up.

State models / Ingredient prioritization / Longitudinal follow-up
04

Skin science & aesthetics

Aesthetic clinics · Skincare brands · CROs

Connect ingredient screening, mechanism analysis and efficacy validation across skin stratification, barrier repair, inflammation and aging.

Skin stratification / Ingredient ranking / Efficacy validation

03 / RESEARCH & VALIDATION

Bring models into
real research settings.

From human tissue validation to hospital research workflows, computational results connect with biological experiments in a shared evidence chain.

UNAGI / IPFDisease dynamics and intervention framework from the UNAGI publicationNature Biomedical Engineering · 2025
RESEARCH CASE · HUMAN TISSUE VALIDATION

Pulmonary fibrosis:
from virtual screening to human PCLS.

UNAGI models idiopathic pulmonary fibrosis (IPF) progression, prioritizes drug candidates and compares predictions with treatment responses in human precision-cut lung slices (PCLS).

  • Disease trajectories & candidate priorities
  • Mechanisms & human tissue responses
  • Validation results & development pathways
Read the UNAGI paper
COLLABORATION IN PROGRESS · DEMO COMPLETED

Ruijin breast cancer
SIDISH Agent

Natural-language research requests connect to SIDISH tools to generate four report sections for clinician review: patient/cohort profiles, high-risk cell characteristics, virtual perturbations and integrated findings.

Research requestSIDISHFour-part report
Explore the underlying research
JOINT VALIDATION · PROJECT DELIVERY

Candidates, mechanisms
and experiments, connected.

Work with Luohua Biology and other validation partners on cell, organoid and organ-on-chip studies. Candidate packages bring together rankings, mechanism evidence, validation results and development recommendations.

CellsOrganoidsOrgan-on-chip
Discuss joint validation

05 / THE TEAM

Connecting science,
data and delivery.

Scientific strategy, project delivery and clinical statistics work together, supported by a team developing, evaluating and delivering models and platforms.

Jun Ding
Founder & CEO

Jun Ding

Scientific strategy · Platform direction · International research

Associate Professor in the Faculty of Medicine at McGill University and an affiliate member of Mila. Research in computational biology, single-cell omics and AI disease modeling.

Academic profile
Sheng Yuan
Project Director

Sheng Yuan

Project management · Industry research · Delivery

Coordinates project scope, schedules, acceptance and product delivery, with cross-functional collaboration and bilingual communication.

Ying Wang
Clinical Statistics Lead

Ying Wang

Biostatistics · Cohort design · Translational validation

Leads endpoint definition, statistical methods, clinical cohort studies and real-world data analysis, connecting data quality with interpretation.

Technical team

Model development · Data analysis · Evaluation · Platform delivery
Jingtao Wang

Jingtao Wang

Single-cell modeling & active learning

Bowen Zhao

Bowen Zhao

Single-cell deep learning

Guo Jiang

Guo Jiang

Multimodal biomedical AI

Yumin Zheng

Yumin Zheng

Disease dynamics & drug discovery

Kailu Song

Kailu Song

Single-cell omics & AI drug discovery

06 / WORK WITH US

Start with a question.
Build a collaboration.

Choose the depth of collaboration around your research needs, from project analysis and validation to licensing and co-development.

01

Projects & CRO services

Address a defined disease or efficacy question with models, candidate lists, mechanism reports and validation plans.

02

Validation & candidate packages

Bring candidate priorities, mechanistic evidence and experimental results together for the next development decision.

03

Platform & model licensing

Support ongoing analysis, automated reporting and versioned model assets through SaaS, APIs or on-premises deployment.

04

Co-development

Advance candidates, indications and efficacy-focused products with industry partners through milestone-based collaboration.

PARTNER WITH MIMESIS

Your next research question
starts here.

Tell us about your disease area, data and research goals. Together, we can define the models, deliverables and validation pathway.

Contact the team jun.ding@mcgill.ca